Why YVOIRE

From HA raw material to end product

by LG Chem

LEFT PAGE RIGHT PAGE
  • home
  • YVOIRE

  • >

  • WHY YVOIRE

YVOIRE INTRODUCTION YVOIRE INTRODUCTION

Distinguished HA raw materials

LG Chem has developed and manufactured hyaluronic acid pharmaceutical products 25 years.

1990HA R&D started with Producer Strain Development

1995Hyal 2000 Inj.,1st HA Ophthalmic Viscoelastics launchedin Korea Hyruan plus Inj., 1st 3-Injection HA Osteoarticular

2000Viscosupplement launched in Korea

2010YVOIRE, 1st Cross-linked HA Filler launched in Korea

2013YVOIRE plus, 1st HA Filler with Lidocaine launched in Korea

  • YVOIRE MATERIALS YVOIRE MATERIALS
  • Authorized quality

    Reliable HA material listed to USFDADMF 1)

    and certificated byFDADMF 2)

    LG Chems’ non-animal origin HA has been marketed in various medical fields since 1995 with proven safety and efficacy. Its high molecular weight HA has been approved by the European Directorate for the Quality of Medicinesand its drug master file has been filed to the US FDA.

HICETM Cross-linking Technology

HICETM Cross-linking Technology, which enables to reach the maximum cross-linking ratio despite of “minimal use of cross-linkers” by dispersing the cross-linkers into highly concentrated HA during cross-linking reaction.

HICE Cross-linking Technology HICE Cross-linking Technology

Cross-linking ratio of HA filler products

HICE Cross-linking Technology HICE Cross-linking Technology
  1. 1. Drug master file No. 17416, FDA

  2. 2. Certification of Suitability of monographs of the European Pharmacopoeia, EDQM

  3. 3. Galderma’s patent, WO 2014/206701 A1